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ARTICLE
Reduced Neuron-Speciﬁc Expression of the TAF1 Gene Is
Associated with X-Linked Dystonia-Parkinsonism
Satoshi Makino, Ryuji Kaji, Satoshi Ando, Maiko Tomizawa, Katsuhito Yasuno, Satoshi Goto,
Shinnichi Matsumoto, Ma. Daisy Tabuena, Elma Maranon, Marita Dantes, Lillian V. Lee,
Kazumasa Ogasawara, Ikuo Tooyama, Hiroyasu Akatsu, Masataka Nishimura, and Gen Tamiya
X-linked dystonia-parkinsonism (XDP) is a movement disorder endemic to the Philippines. The disease locus, DYT3, has
been mapped to Xq13.1. In a search for the causative gene, we performed genomic sequencing analysis, followed by
expression analysis of XDP brain tissues. We found a disease-speciﬁc SVA (short interspersed nuclear element, variable
number of tandem repeats, and Alu composite) retrotransposon insertion in an intron of the TATA-binding protein-
associated factor 1 gene (TAF1), which encodes the largest component of the TFIID complex, and signiﬁcantly decreased
expression levels of TAF1 and the dopamine receptor D2 gene (DRD2) in the caudate nucleus. We also identiﬁed an
abnormal pattern of DNA methylation in the retrotransposon in the genome from the patient’s caudate, which could
account for decreased expression of TAF1. Our ﬁndings suggest that the reduced neuron-speciﬁc expression of the TAF1
gene is associated with XDP.
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X-linked dystonia-parkinsonism (XDP [MIM314250]) is
characterized by severe progressive torsion dystonia fol-
lowed by parkinsonism.1 Its prevalence is high (5.24 in
100,000) on Panay Island, Philippines.2 Dystonia is a syn-
drome of sustained muscle contractions causing twisting
and repetitive movements or abnormal postures,3 and its
pathogenetic basis is still unclear. XDP has a well-deﬁned
pathology of extensive neuronal loss and mosaic gliosis
in the striatum (caudate nucleus and putamen),4,5 which
appears to resemble that in Huntington disease (MIM
143100). Identiﬁcation of the disease gene of XDP may
contribute to the elucidation of the molecular basis un-
derlying not only XDP itself but also other diseases in
which basal ganglia show neurodegeneration, such as
Huntington disease and Parkinson disease.
A series of linkage analyses has mapped the disease lo-
cus, DYT3, to Xq13.1 (ﬁg. 1).6,7 A linkage disequilibrium
study narrowed theDYT3 locus towithin a 350-kb interval
on Xq13.1.8 Subsequently, Nolte et al.9 used PCR-based
sequencing and screening analyses to report four SNPs and
ﬁve disease-speciﬁc sequence changes (DSCs) in the “mul-
tiple transcript system” (MTS) within 260 kb of the DYT3
region. However, PCR often fails to detect large sequence
variants such as transposons. Moreover, the previous
study of MTS did not include any brain specimens from
patients with XDP. Therefore, the structure and expression
of MTS transcripts are still unclear.
We performed the following studies to reveal the dis-
ease-causative gene of XDP. To ﬁnd all disease-speciﬁcmu-
tations within the DYT3 region, we ﬁrst performed ge-
nomic sequencing analysis to accurately determine the
complete DNA sequence of this region.We also performed
detailed expression analysis of the gene in brain specimens
obtained from patients with XDP, because the expression
of disease genes can be tissue speciﬁc. To determine the
complete structure of the disease gene, we used a library
consisting of “full-length” cDNAs frequently containing
their 5′ ends.10
Material and Methods
Subjects and Samples
The study included 67 Filipino individuals (20 affected males)
from 16 families residing in Panay. Information on all the patients
is listed in table 1. All patients had the disease-speciﬁc haplotype
between DXS10017 and DXS10018 in the DYT3 region that had
been deﬁned elsewhere.8,9 For construction of the BAC contig and
portions of the RNA analysis, lymphoblastoid cells were immor-
talized by infection with the Epstein-Barr virus. This study in-
volved a total of 137 healthy control subjects: 14 unrelated Fil-
ipinos, 44 Japanese, 38 African Americans, and 43 European
Americans. Materials from the non-Filipino individuals were
commercially provided by Coriell Cell Repositories. We used
seven postmortem brains from seven male Filipino patients who
had XDP. One of the seven brain specimens was frozen, and six
were formalin ﬁxed immediately at autopsy. The information on
these seven patients with XDP is provided in table 2. We used
the frozen brain from a single patient with XDP for long RT-PCR,
Figure 1. Genomic sequencing analysis of the DYT3 region. a, Physical map of the DYT3 critical region on Xq13.1. Annotated genes
in this region that have experimentally veriﬁed coding sequences (and their proteins) include NLGN3 (neuroligin 3), GJB1 (gap junction
protein, beta-1), ZNF261 (zinc ﬁnger protein 261), NONO (non-POU domain–containing octamer-binding protein), ITGB1BP2 (melusin
[integrin beta-1 binding protein 2]), TAF1 (TAF-250 [TATA-binding protein-associated factor, 250 kDa]), ING2 (inhibitor of growth 2),
OGT (O-linked N-acetylglucosamine transferase), ACRC (acid repeat–containing gene), and CXCR3 (chemokine, CXC motif, receptor 3).
The broken arrow indicates MTS. A unique Southern probe was designed for the HindIII-digested fragment containing the SVA retro-
transposon insertion. Eight BAC clones comprising a continuous contig map cover 462,651 bp, from 66572462 to 67035112 in NCBI
build 30. A total sequence length of 463,567 bp was determined, with 5.7-fold redundancy. Also shown is the distribution of 159
nucleotide variants that were identiﬁed by sequencing. None of these variants is located in any exon of these genes, including their
alternative splicing forms. A red arrowhead indicates the SVA insertion. b, The SVA insertion in the XDP-related and healthy control
populations. Information on the patients with XDP is given in table 1 (patients 1–13). The SVA insertion produces a 6.1-kb fragment,
whereas the wild type produces a 3.4-kb fragment. Arrowheads in the gel indicate female individuals. Carriers are deﬁned as mothers
or daughters of patients with XDP. Possible carriers are daughters or sons of these carriers. NC p negative control.
www.ajhg.org The American Journal of Human Genetics Volume 80 March 2007 395
Table 1. Information on All the Patients with XDP Who Were Studied by Southern
Hybridization
Patient
Number Sample
Signal
Age at
Onset
(years) Clinical Description6 kb 3 kb
1 XD001   31 Generalized dystonia
2 XD002   38 Generalized dystonia
3 XD011   29 Muscle atrophy and generalized dystonia
4 XD013   45 No atrophy and dystonia
5 XD015   31 Limb atrophy and parkinsonism
6 XD024   41 Dystonia and parkinsonism
7 XD027   30 Dystonia and parkinsonism
8 XD028   30 Leg tremor and generalized dystonia
9 XD033   33 Parkinsonism (hand tremor)
10 XD036   50 Mild dystonia and parkinsonism
11 XD041   52 Dystonia and parkinsonism
12 XD054   30 Generalized dystonia
13 XD062   40 Severe atrophy
14 XD101   42 Swelling feet, difﬁculty walking, and sensory trick
15 XD103   46 Dystonia, parkinsonism, difﬁculty swallowing, and freezing gait
16 XD111   39 Dystonia, parkinsonism, and difﬁculty walking
17 XD112   33 Torticollis and parkinsonism
18 XD115   31 Jaw-opening dystonia and parkinsonism
19 XD131   36 Blephalospasm and writer’s clamp
20 XD141   40 Cervical dystonia, axial dystonia, and parkinsonism
NOTE.—All patients are male. Plus sign () p presence of signal; minus sign () p absence of signal.
Table 2. Information on All the Patients with XDP Who Were Studied by Expression Analysis
Patient
Number
Age
(years)
Clinical Description
Cause of
Death Fixation Examination(s)a
At
Onset
At
Death
1b 42 52 Dystonia and parkinsonism Pneumonia Frozen; 4% paraformaldehyde NB, LRT, QRT, ISH
2 40 54 Dystonia and parkinsonism Pneumonia Formalin IHC
3 23 47 Dystonia and parkinsonism Pneumonia Formalin IHC
4 56 59 Dystonia Suicide Formalin IHC
5 38 52 Dystonia Unknown Formalin IHC
6 35 42 Dystonia Suicide Formalin IHC
7 34 46 Dystonia Pneumonia Formalin IHC
NOTE.—All patients are male.
a IHCp immunohistochemical staining; ISHp in situ hybridization; LRTp long RT-PCR; NBp northern blot; QRTp quantitative
RT-PCR.
b The results for patient 1 are presented in ﬁgures 2, 4, 5a–5e, 6, and 7.
northern analysis, quantitative RT-PCR, and in situ hybridization.
In addition, we used the six formalin-ﬁxed brain specimens for
immunohistochemical staining. This study complied with the
ethical guidelines of the institutions involved.
Genome Analysis
We constructed two series of BAC libraries, using genomic DNA
from a patient with XDP who was aged 41 years and had gen-
eralized torsion dystonia without parkinsonism. Cultured lym-
phoblastoid cells from a patient with XDP were embedded in
agarose plugs, and then high–molecular-weight DNA was par-
tially digested with EcoRI and was size fractionated by pulse-ﬁeld
gel electrophoresis. Size-fractionated DNA was cloned into the
CopyControl pCC1BAC vector (Epicentre) and was transformed
into DH10B cells by use of an electroporator. The same procedure
was repeated with HindIII. We identiﬁed BACs covering theDYT3
region by hybridizing 32P-labeled PCR probes to ﬁlters generated
from these BAC libraries. A shotgun library in pUC118 was con-
structed from each BAC clone. Cycle sequencing was performed
using a BigDye Terminator v3.1 Cycle Sequencing kit (Applied
Biosystems) and was analyzed on anABI 3700 capillary sequencer.
The gap clones were sequenced using a GPS-1 Genome Priming
System (New England Biolabs). Raw sequence data were analyzed
and assembled by ATGC software (Genetyx).
We digested 4 mg of genomic DNA in 300 ml of a standard
reaction mixture containing 125 units of HindIII for 3 h at 37C.
For methylation detection, an aliquot of the HindIII-digested
DNA was digested under the same conditions with a CpG meth-
ylase–sensitive enzyme, HpaII. As a control reaction, an aliquot
was also digested with MspI, which is a CpG methylase–insen-
sitive isoschizomer of HpaII. After ethanol precipitation, the di-
gested DNA was loaded onto a 0.8% agarose gel in 0.1# Tris-
borate-EDTA buffer for electrophoresis. After denaturation and
the subsequent neutralization steps, the DNA was transferred to
a positively charged nylon membrane (Roche Diagnostics). The
ﬁlter was prehybridized for 1 h in DIG Easy Hyb buffer (Roche
Table 3. PCR Primer Sets for Fragment Ampliﬁcation from the TAF1 cDNAs
Fragment
Name
Forward Primer Reverse Primer
Amplicon
Size
(bp)Namea
Sequence
(5′r3′) Tm
b Namea
Sequence
(5′r3′) Tm
b
TA01 TAF_f_3 GGGAGCTCAGTAFAGTCACTTCTG 60.6 TAF_r_400 CCACCTCATTGATGTCTGAATAG 59.6 398
TA02 TAF_f_377 ACTAFTTCAGACATCAATGAGGTGG 60.4 TAF_r_772 TGGCATCATGCTGCATAATC 61.8 396
TA03 TAF_f_755 TTAFTGCAGCATGATGCCAC 60.4 TAF_r_1175 CCCAGCATATCATACCACAGTC 60.4 421
TA04 TAF_f_1152 CCGACTGTGGTAFTGATAFTGCTG 61.5 TAF_r_1550 CGTCCATATACCAGATCCTCATTG 62.7 399
TA05 TAF_f_1528 AATGAGGATCTGGTAFTAFTGGACG 60.2 TAF_r_1910 CGTAATTCCACAGCAGGAATTG 62.7 383
TA06 TAF_f_1889 CAATTCCTGCTGTGGAATTAFCG 62.7 TAF_r_2273 CCATATTTACAATCTGGTGCTCC 60.7 385
TA07 TAF_f_2251 GGAGCACCAGATTGTAFAATAFTGG 60.7 TAF_r_2598 TTCCATTCGTATCCTCCGTG 62 348
TA08 TAF_f_2580 ACGGAGGATAFCGAATGGAAG 60.1 TAF_r_2979 ATCTGCCACCCCAGTCAC 60.8 400
TA09 TAF_f_2945 GCAAGTGTCTGCTAFGAGGTGAC 60.3 TAF_r_3331 GTAGGTCAAAGATGCGCTGAC 61 387
TA10 TAF_f_3311 GTCAGCGCATCTTTGACCTAFC 61 TAF_r_3710 GTCCGTATGCGCACATAGG 61.3 400
TA11 TAF_f_3689 ATGCCTAFTGTGCGCATAFCG 61.8 TAF_r_4089 CAAGACAATTTTGGTCCCTTC 59.6 401
TA12 TAF_f_4069 GAAGGGACCAAAATTGTCTTG 59.6 TAF_r_4467 TAGCTCCAGATGCTCTCTGAAC 59.9 399
TA13 TAF_f_4413 CGTGCGTAFAACGCCTCTAFC 60.6 TAF_r_4808 CGACTCTGATACTTGTGCTTGG 61 396
TA14 TAF_f_4780 AACATCTCCAAGCACAAGTAFTCAG 60.7 TAF_r_5164 GCTTTTCTGGAGTGGCACTG 62.1 385
TA15 TAF_f_5130 TGTCTTGGATAFTTCCCAGTGC 61.1 TAF_r_5505 GTTGCTATCCTCCAAACCATG 60.5 376
TA16 TAF_f_5482 TCCCATGGTTTGGAGGATAFG 60.9 TAF_r_5862 AAGGCTAAGGTGTTAGTTAATTTCATG 60.3 381
TA17 TAF_f_5834 ATCATGAAATTAFACTAFACACCTTAFGCC 60.1 TAF_r_6231 TTAGTAGAGATGCGGTTTCGC 60.5 398
TA18 TAF_f_6073 GTAFACTTTAFTGTCCTCTTGATGTAFTTAFGG 59.1 TAF_r_6469 CAGGAGGGCTCTCATCTGC 62.3 397
TA19 TAF_f_6451 GCAGATGAGAGCCCTCCTG 62.3 TAF_r_6855 AAGGATCTGATAGAGTGCTTATCATG 60.2 405
TA20 TAF_f_6831 ATGATAFAGCACTCTAFTCAGATCCTTG 60.2 TAF_r_7164 CACACTCTGCCATTTCTAGACTG 60.1 334
TA21 TAF_f_7140 CACAGTCTAFGAAATGGCAGAGTG 60.1 TAF_r_7553 GGGTTATCATTGTGAACAGTTAGC 59.9 414
TA22 TAF_f_7277 GGCAGGAAGTAFTAFTCATCACAAGC 62.1 TAF_r_7606 CCAGCATACATAACAAACACAGAAG 60.9 330
MT23c TAF_f_7277 GGCAGGAAGTAFTAFTCATCACAAGC 62.1 pMTS-r GTGAGAGCTCAAAGACCAATAAG 58.3 779
Probe 1 TA_f_2333 TGCAAGCATTTGAGAACAACCT 62 TA_r_2690 GAGTCCATCCCTGTGCGTT 61.1 358
Probe 2 TA_f_4786 TCCAAGCACAAGTATCAGAGTCG 61.7 TA_r_5185 CTTCACCTTCCTGTGTTACCTGCT 63 400
Probe 3 TA_f_5637 GAGCGTACTAAGCCAGGTCCA 61.7 TA_r_6065 TTCATAATTTCCCCTCCTTCCC 62.4 393
NOTE—The PCR mixture contained 2 ml of the ﬁrst-strand cDNA, 0.2 mM of each dNTP, 1 mM of each primer, 1# GeneAmp PCR buffer, and 2.5
units of AmpliTaq Gold DNA polymerase, in a 50-ml total volume. The PCR conditions were 9 min at 95C, followed by 35 cycles at 95C for 45 s,
60C for 45 s, and 72C for 60 s.
a The value in the third part of the primer name represents position in a major form of the TAF1 transcript.
b Tm p annealing temperature (C). The calculation conditions were 1,000 nM of each primer and 50 mM potassium ions.
c The primer set was used only for ﬁrst-strand cDNA from MTS.
Table 4. Primers and Probes for the TaqMan Expression Assay
Assay Name
Primer Sequence
(5′r3′)
Reporter 1 Sequencea
(5′r3′)
Amplicon Size
(bp)Forward Reverse
TAF1-5′ GACTGACGGTGCCTTGGT GTCTGAATAGTCCACAGCATCTTCT ACCCACCCTTCATCATTT 70
TAF1-3′ ACCTTATTCTGGCCAACAGTGTT ACAATCTCCTGGGCAGTCTTAGTAT ACTCTCAGGTCCATTATAC 73
TA02-334 TGGGACCAATGAAGAAGGATAAGGA ATTCTGAGTCAGAGGAACTACTGAAGT CCACTTTCTCACCAGTAATAG 81
TA08-269 CTCTGCGCTGACTTCAAACG TTCCTCATTTTCTTCTTCTGGAGCAA CCATAGCCAGCATCCTGT 79
TA09-391 GTGGTGAAGGATTCTCCTATGTGAA ATCTGTTCCTGTCACTGTCTTCTTC CAGCAGAAGGTAGGATGATAA 105
TA09-693 TGCCAAGCAACTTCTACGTAAATTTG TCCAACTCTATACAAAGCCCCTAGT CACACTCACCCTCTTCC 99
TA14-317 ACCTTATTCTGGCCAACAGTGTT CCTCCAAAGCTGCTTCTTTAGCA TTGAGTCAAATGTTCATCATACATT 97
TA14-389 GGAGATTGTGAACGTCTGTTACCA TCCTTCTCAAGTTGAGTCAAATGTTCAT CATACTACCTCAGTCAATGTC 73
TA14-391 CCCCAGGGCCCTACAC CTGAGGGATGTGTTGGTATCATACAA CCTCAGGCTAAGCCTC 64
TA14-407 GGGAGAGCTTTCTGGATGATGTAAA ACAATCTCCTGGGCAGTCTTAGTAT CTGACTCTCAGGTCCTGCACG 119
TA15-477 AGTGCCACTCCAGAAAAGCA CCTCGCCCAGCCTACCT CCTGGCGCATCTGTGT 61
TA18-261 GTGGCTCACACCTGTAATCTCA CCTCCCGGGTTCAAGTAATTCTC CAGCCTCCCAGAGTGC 67
TA14-385Nb CCCCAGGGCCCTACAC CTGAGGGATGTGTTGGTATCATACAA CCTCAGCCTCCTGATT 58
TAF1-M GCTAAAGCTCTGCGCTGACT TTAAGCACCCACCAGTTTGAGT CATCCCTGTGCGTTTGA 60
TAF1-3′N CCCAGTGCCACTCCAGAAAA CAGTTCCTTCCTCTTCATCTGCAA ACCTTCCTGTGTTACCTGC 82
MTS-V4 TTGCTCTTGGGCTCTGCATT CTGGCACGGATTTTCACTATCTT ACTCCTTACAGGTACCAATGA 251
MTS-37/1 CCCATGGTTTGGAGGATAGCA CATCTCTGAATGGCTTGTTCATTG TCAGGTGATGAACTTCAATA 166
MTS-37/3 CCCATGGTTTGGAGGATAGCA TCGTTGCTCCAGAGATCTTTGTG ACATCAGGTACCAATGAAC 83
MTS-2/3 GGCCTCCGGCATTGCT TCGTTGCTCCAGAGATCTTTGTG TCCACTGTACCAATGAA 112
MTS-32′/34′ CAACAGTGTTAAGTATAATGGGTACATGTG CTGAGGGATGTGTTGGTATCATACAA TCAGGCTAAGCCTCCT 268
MTS-3/4 GTGTCCGGAGTTGGTTCCT TGGCACGGATTTTCACTATCTTCA CCTTCGCGCTTCAGGC 105
a For the reporter 1 sequences, the dye was FAM.
b This probe is designed to detect all isoform sequences not containing exon 34′.
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Figure 2. Northern analysis. a, Three probes for northern hybridization to TAF1 (detailed information on these probes is given in table
3). b, Total RNA samples from the caudate and lymphoblastoid tissues. The hybridization signal seen at ∼7 kb, which represents TAF1,
was observed in every lane, but a signal was never seen at the smaller sizes corresponding to MTS transcripts reported elsewhere. This
result suggests that the sequences of TAF1 isoforms have such small differences in size, probably less than a few hundred base pairs,
that standard northern analysis cannot discriminate between them in 1% agarose gels denatured by 2% formaldehyde. A probe for
GAPDH was also hybridized to each membrane as a loading control. Mp DIG-labeled molecular-weight marker. c, Relative TAF1 expression.
The hybridization signal seen at ∼7 kb, representing TAF1, had a tendency toward slight reduction in patient caudate, so, to conﬁrm
this, TaqMan assays were performed.
Table 5. All Nucleotide Variants in the
DYT3 Critical Region on Xq13.1
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Diagnostics) and then was hybridized overnight (16–18 h) at
40C. The PCR probe was ampliﬁed using primers XD_probe-F
(5′-AGCTTTGCTGCCATTG-3′) and XD_probe-R (5′-AAGACCCTT-
ATTATTCATGAGTG-3′). After washing the ﬁlter for 30 min at
68C in DIG Wash and Block buffer, drops of 1/100-diluted di-
sodium 3-(4-methoxyspiro {1,2-dioxetane-3,2′-(5′-chloro) tricyclo
[3.3.1.13,7]decan}-4-yl) phenyl phosphate (CSPD [Roche Diagnos-
tics]) were added and the ﬁlter was exposed to x-ray ﬁlm for 1–
5 h.
RNA Isolation
Total RNA was isolated from caudate, cortex, and accumbens of
a frozen brain by use of an RNeasy Lipid TissueMidi kit (QIAGEN)
with a DNaseI treatment step, after homogenization with a Po-
lytron PT1300D (Kinematica). Total RNA from lymphoblastoid
cell lines was also isolated by the same procedure. RNA sources
from six Japanese brains were used as neurologically healthy con-
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Figure 3. The SVA insertion in an additional seven patients with XDP and their relatives, from four families. Information on these
patients is given in table 1 (patients 14–20).
trols by the same procedure. Also, two commercial human brain
RNA sources were used as controls—cerebral cortex total RNA
(catalog number 636561) and caudate nucleus total RNA
(63566)—along with human tissue total RNA sources from heart
(64100), spleen (64093), lung (64092), liver (64099), and thymus
(64107), provided by BD Bioscience Clontech, and stomach
(735038), provided by Stratagene. The quality and quantity of
total RNAs were assessed using an Agilent 2100 Bioanalyzer (Agi-
lent). The 2:1 ratio of 28S:18S rRNA was employed as a threshold
for intact RNA. The quantity was conﬁrmed by the RiboGreen
RNA ﬂuorescence assay (Molecular Probes).
Northern Analysis
For synthesis of riboprobes, we performed PCR and cloning into
the TA-vector (Promega), using the three primer sets in table 3:
TA_f_2333 and TA_r_2690 for probe 1, TA_f_4786 and TA_r_5185
for probe 2, and TA_f_5637 and TA_r_6065 for probe 3. Total RNA
samples of 10 mg were loaded into a 1% agarose gel denatured
by 2% formaldehyde gel. The gel was run in 1# 3[N-Morpho-
lino]propanesulfonic acid buffer. After electrophoresis, the RNA
was transferred to a positively charged nylon membrane. After
prehybridization for 1 h in DIG Easy Hyb buffer at 68C, hybrid-
ization was performed overnight (16–18 h) at 68C. The ﬁlters
were washed twice for 5 min with 100 ml of 2# saline sodium
citrate (SSC) and 0.1% SDS at room temperature and then were
washed twice for 15 min with 0.1# SSC and 0.1% SDS at 68C.
We employed the standard conditions and procedure provided
by Roche Diagnostics.
Long RT-PCR Analysis
Long RT-PCR analysis was performed in two steps: (1) ﬁrst-strand
synthesis from RNAs of the control and XDP caudates by long
reverse transcription (RT) and (2) fragment PCR by use of the
long RT products (i.e., cDNA) as a template. Such a long RT-PCR
method is known to be effective for deﬁning the extent of a large
transcript.11 The two parts revealed not only the extent of the
transcripts but also alternative exons included in the transcripts.
Long RT was performed using TAF_r_7621 for the TATA-binding
protein-associated factor 1 gene (TAF1 [MIM 313650]) andMTS_r
for MTS as the long RT primer.
Quantitative RT-PCR
cDNA was synthesized from the total RNA by use of random
hexamers with a TaqMan Reverse Transcription Reagents kit (Ap-
plied Biosystems). All the primers and probes are listed in table
4. We also employed a control probe for 18S rRNA (4319413E)
and the glyceraldehyde-3-phosphate dehydrogenase gene
(GAPDH) (4310884E) and examined a probe for the dopamine
receptor D2 gene (DRD2) (Hs00156514_m1). We used a ﬁnal con-
centration of 250 nM probe, 900 nM primers, and 50 ng cDNA
in a 50-ml reaction volume in a 96-well reaction plate on an ABI
PRISM 7000 in accordance with the standard procedure. The con-
ditions of real-time PCR consisted of a holding step for 2 min at
50C and 1 min at 95C followed by 50 cycles for 15 s at 95C
and 1 min at 60C. Quantity was calculated every time by use of
a standard curve for each well. All quantitative data normalized
by adjustment for 18S rRNA were tested by Smirnov’s test with
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Figure 4. Long RT-PCR and the alternative exons of TAF1. a, Long RT-PCR analysis. The broken line indicates an expected cDNA
fragment of TAF1 with the long RT primer on the end of exon 38 (short arrow). By subsequent PCR with the use of the long cDNA, six
lanes—TA02, TA08, TA09, TA14, TA15, and TA18 (red bars)—showed multiple bands. Other lanes (black bars) contained single bands.
Also shown is the result obtained using the MTS-speciﬁc long RT primer on its 3′ end. There was no difference between the TAF1 and
MTS primers or between the patient and the control results (patient data not shown). Scale kb. b, Ten alternative exons,barp 1
including two exon skippings and one deletion, were identiﬁed by RT-PCR. The detailed sequence information for these exons is
annotated in our AB191243 deposition in DNA Databank of Japan (DDBJ). Of 10 alternative exons, 3 were reported elsewhere as exons
of MTS, but a form including both exon 32′ and exon 34′ was not detected. For quantitative RT-PCR, 17 TaqMan probes were designed.
Two TAF-series probes (red) and 10 TA-series probes (pink) were designed to detect mainly the TAF1 common forms and alternative
splicing isoforms, respectively. The other ﬁve MTS-series probes (orange) were designed to detect the MTS transcripts reported elsewhere.
Var. p variant. Scale kb.barp 5
a 5% signiﬁcance level. We used Student’s t test to test the dif-
ference in means of the expression levels between patients with
XDP and healthy control caudate nuclei, after checking the ac-
ceptance of the quality of variances between the two groups by
the F test.
In Situ Hybridization
Synthesis of DIG-labeled riboprobes for TAF1 (probe 3 in ﬁg. 2a),
as well as for b-actin (ACTB) and glial ﬁbrillary acidic protein
(GFAP) as controls, was performed according to the procedure
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Table 6. Linearity of Ampliﬁcation Curve from Threshold
Cycle (Ct) p 25 to Ct p 35
Assay Slope (SD) r (SD) (SD)2r
MTS-37/1 .0020 (.0032) .31 (.641) .48 (.226)
MTS-37/3 .035 (.0123) .82 (.036) .68 (.061)
MTS-V4 .011 (.0098) .51 (.422) .43 (.285)
MTS-2/3 .00016 (.0014) .10 (.580) .32 (.213)
MTS-32′/34′ .00073 (.0005) .77 (.258) .65 (.292)
MTS-3/4 .054 (.0351) .81 (.017) .66 (.032)
TA14-385Na 1.37 (.0424) .99 (.002) .97 (.004)
NOTE.—Slopes of the resulting lines, correlation coefﬁcient (r) values,
and coefﬁcient of determination ( ) values were calculated by curve-2r
ﬁtting with linear function against normalized reporter signal (DRn)
values from Ct p 25 to Ct p 35 in each ampliﬁcation curve of the real-
time PCRs. We employed the threshold with slope 10.5 and .2r 1 0.6
a The TaqMan probe was employed as a positive control to show stan-
dard ampliﬁcation and linearity from Ct p 25 to Ct p 35.
used for northern analysis. The caudate blocks were ﬁxed with
4% paraformaldehyde. After cryoprotection, serial 20-mmsections
were cut in a cryostat. The sections were reacted with alkaline
phosphatase–labeled anti-DIG antibody (diluted 1:200 [RocheDi-
agnostics]) in 1% skimmilk in sodium Tris (hydroxymethyl)-ami-
nomethane (NT) buffer. After washing with NT buffer, the posi-
tive signals were detected by nitroblue tetrazolium chloride
(Roche Diagnostics) and 187 mg/ml 5-bromo-4-chloro-3-indolyl-
phosphate (Roche Diagnostics).
Immunohistochemical Staining
The six tissues from six different patients with XDP were ﬁxed
in 10% neutral formalin, were sliced, and were embedded in par-
afﬁn, and 3-mm sections were cut on a microtome and were
mounted on Matsunami adhesive silane–coated glass slides. After
routine deparafﬁnization, rehydration, and blocking of endoge-
nous peroxidase activity, all sections were processed for micro-
wave-enhanced antigen retrieval. The sections were blocked with
3% BSA in PBS (pH 7.2) for 1 h and thenwere incubated overnight
at room temperature in 3% BSA-PBS containing goat polyclonal
antibody against TAF1 (diluted 1:5,000 [SantaCruz]). Rabbitpoly-
clonal antibody against GFAP (Dako) was also used as a control.
For the visualization of bound antibodies, we used Histoﬁne Sim-
plestain Max-PO (G) (Nichirei) and the liquid diaminobenzidine
(DAB) substrate chromogen system (Dako Cytomation). The sec-
tions were further processed for enhancement of theDAB reaction
products by use of a Dako Envision Kit (Dako Cytomation).
Full-Length Cloning and Direct Sequencing of the TA14_391
Isoform
To determine the full-length TAF1 isoform, including the 5′ end
of the transcript, a CapSite cDNA library derived from human
brain (317-04041 [Nippon Gene]) was used. The CapSite cDNA
libraries consist of cDNAs in which the 5′ cap structure (m7Gppp)
of eukaryotic mRNA is replaced with a synthetic oligoribonu-
cleotide to label the 5′ end of the cDNA, enabling identiﬁcation
of the 5′ end sequence by PCR.10 For ampliﬁcation of the 3′ end,
a wholeMarathon-Ready cDNA library derived fromhumanbrain
(BD Biosciences Clontech) was used. The reaction mixture con-
tained 1 ml of the library, 200 mM of each primer, 0.16 mM of
each deoxyribonucleotide diphosphate (dNTP), 1# BD Advan-
tages2 PCR buffer, and 1# BD Advantages2 Polymerase Mix
(639300 [BD Biosciences Clontech]) in a total volume of 50 ml.
The PCR consisted of denaturation for 30 s at 94C, followed by
5 cycles for 5 s at 94C and 10 min at 70C and then 20 cycles
for 5 s at 94C and 10 min at 78C. An aliquot of the ﬁrst PCR
product was used for the second PCR reaction under the same
conditions as the ﬁrst-round PCR but with different primers. We
used a primer set for the ﬁrst PCR—ﬁrst RDT primer (Nippon
Gene) and TA3_r_5070 (5′-GGTATCATACAAATCAGGAGGCTT-
3′)—and then used a set for the second heminested PCR—second
primer and TA3_r_5070. These primers were puriﬁed by PAGE
extraction. Alternative exon 34′–speciﬁc primers were designed
to prevent erroneous ampliﬁcation due to PCR slippage. For am-
pliﬁcation of the 3′ end, a whole Marathon-Ready cDNA library
derived from human brain (BD Biosciences Clontech) was used
along with the primer set TA6_f_5032 (5′-CCCTACACGCCTCAG-
GCTA-3′) and TA2_r_7606 (5′-CCAGCATACATAACAAACACAG-
AAG-3′) under the same conditions as those used for the CapSite
cDNA but as a single PCR reaction. Direct sequencing was done
on these PCR products. After puriﬁcation by a PCR Product Pre-
Sequencing kit, cycle sequencing was performed using a BigDye
Terminator v3.1 Cycle Sequencing kit, with 20 internal primers
for a second PCR product from CapSite cDNA and 8 internal
primers for the PCR product from Marathon-Ready cDNA. Di-
rect sequencing was done on two long PCR products by use
of the following primers: TAF_f_377, TAF_f_755, TAF_f_1152,
TAF_f_1528, TAF_f_1889, TAF_f_2580, TAF_f_2945, TAF_f_3311,
TAF_f_3689, TAF_f_4069, TAF_f_4413, TAF_f_4780, TAF_r_2273,
TAF_r_2598, TAF_r_2979, TAF_r_3331, TAF_r_5164, TAF_r_5505,
TAF_r_5862, TAF_r_6231, TAF_r_6469, TAF_r_6855, TAF_r_7164,
TAF_r_7553, and TAF_r_7606 (table 3).
Results
Entire Genomic Sequence of the DYT3 Region
Two series of BAC libraries were constructed using DNA
from a patient with XDP who had a disease-speciﬁc
haplotype8,9 in the DYT3 region. From these libraries, a
continuous BAC contig consisting of eight BAC cloneswas
then generated to cover the DYT3 region between the
GJB1 and CXCR3 genes (ﬁg. 1a). By applying a shotgun
sequencing strategy, we accurately determined the com-
plete DNA sequence of the BAC contig, with 5.7-fold re-
dundancy. The total sequence length of the BAC contig
was 463,567 bp. A comparison between our sequence from
the patient with XDP and a reference sequence from Na-
tional Center for Biotechnology Information (NCBI) build
30 showed a total of 159 sequence variants: 89 single-
nucleotide substitutions, 68 small insertions/deletions (in-
dels), 1 retrotransposal insertion, and 1 large (1,666-bp)
deletion (all variants are listed in table 5). Of these vari-
ants, 53 were known SNPs, comprising 50 substitutions
and 3 indels. Of the 68 indels, 62 were repetitive units of
STRs, and the other 6 indels were also located in certain
types of STRs. The large deletion was a direct repeat se-
quence spanning 1,666 bp. The retrotransposal insertion
in intron 32 of the TAF1 gene (ﬁg. 1a) was 2,627 bp in
length, which is categorized as an SVA (short interspersed
nuclear element, VNTR, and Alu composite) retrotranspo-
son.12,13 The SVA retrotransposon insertion in the DYT3
region had been never reported. However, none of these
Figure 5. Expression of the TAF1 isoforms in the caudate. a, Expressions are shown relative to the expression of 18S rRNA (as an internal
control). The label “relative mRNA expression” means relative mRNA expression level to 1/20# 18S rRNA. Values are expressed as means
 SEM ( ). The TA14-391 probe showed a signiﬁcant reduction in the patient’s caudate. Two-sided P values are shown. Also shownnp 3
is the expression level of TA14-391 (b) and DRD2 (c) in three brain regions: caudate, accumbens, and cortex. All regions showed a signiﬁcant
decrease in TA14-391 expression. d, Morphometry analysis of TAF1-positive cells in XDP and control caudate nuclei. The number of each
type of cell was counted in 1,000,000-mm2 areas of the caudate nuclei. These were gliosis and neuronal loss in the XDP caudate nucleus.
e, In situ hybridization analysis of TAF1. Although many TAF1-positive neurons were observed in both tissues, the expression level was
apparently low in the patient’s caudate neurons, even when a common probe for exon 38 was used. By contrast, the expression level of
TAF1 in glial cells was weak in both tissues. ACTBpb-actin; GFAPp glial ﬁbrillary acidic protein. Strong ACTB signals were shown in glial
and neuronal cells. The GFAP probe stains active glial cells, especially in the XDP caudate nucleus, because of activation by astrogliosis.
In contrast, we observed no signal when using sense probes of these genes (data not shown). Scale mm. f, TAF1 immunohis-barp 25
tochemical staining. Nearby sections were stained with polyclonal antibodies against TAF1, calcineurin (CALN), and GFAP. The immuno-
reactivity of TAF1 in the XDP caudate neurons was apparently weak. Moreover, the immunoreactivity of TAF1 in glial cells was originally
weak in both tissues. Similar immunoreactivity was observed in three other brain tissues from three different patients with XDP. Scale
mm.barp 25
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Table 7. Abundance of the Probe TA14-391 in Various
Tissues and Cell Lines
Tissue or Cell Line
Mean (SE)
[105 fmol per 100 ng RNA]
TA14-391 TAF1 Major Form
Lymphocytes 0 3.68 (.08897)
Heart 0 .0873 (.00484)
Spleen 0 3.13 (.06749)
Lung 0 .133 (.00536)
Liver 0 4.20 (.21582)
Thymus 0 1.44 (.07147)
Stomach 0 1.23 (.03865)
Caudate .699 (.00761) 3.30 (.50351)
Cortex .463 (.00308) 3.70 (.57268)
Neuroblastoma, SH-SY5Y .213 (.00694) 4.68 (.55110)
Glioblastoma, HTB15 0 1.67 (.44595)
NOTE.—The abundances for TA14-391 and the TAF1 major form (TA14-
385N) were determined using quantitative RT-PCR by use of each clone
of known concentration in the plasmid as an internal control.
variants was located in any exon or promoter of the an-
notated genes that have experimentally veriﬁed coding
sequences, including their alternative splicing exons. In
the region between DXS10017 and DXS10018, there were
25 variants, which included the SVA insertion and the
1,666-bp deletion. We conﬁrmed these variants in an eth-
nic panel (see the “Material and Methods” section) that
included patients with XDP who have the disease-speciﬁc
haplotype. DSCs 12, 10, 1, 3, and 2 were disease-speciﬁc
among patients with XDP tested here as well as in a pre-
vious report.9 The 1,666-bp deletion was detected by PCR
among all affected and unaffected Filipinos and in the
ethnic panels (data not shown) and was considered to be
nonspeciﬁc. By contrast, the SVA retrotransposon was
clearly disease speciﬁc in our data set (ﬁgs. 1b and 3). These
disease-speciﬁc variants, the DSCs and the SVA retrotrans-
poson, were located around the TAF1 and MTS genes.
Previously Proposed MTS Transcripts
Next, northern hybridization and long RT-PCR analysis
were undertaken to conﬁrm the structures and expression
of the TAF1 and MTS genes. Northern analysis showed
that the hybridization signal seen at ∼7 kb of TAF1 had a
tendency toward reduction in patient caudate and that
the MTS transcript lengths reported elsewhere9 were not
detectable in RNAs from either patient or control tissues
(ﬁg. 2b). Long RT-PCR analysis showed that the PCR frag-
ment pattern from MTS was identical to that from TAF1
(ﬁg. 4a). If the MTS transcripts had lacked upstream exons
1–29 and exon 38, spanning 12 kb, as shown in the pre-
vious report,9 the northern analysis would have detected
the corresponding signals at ∼2–5 kb. Moreover, our long
RT-PCR analysis showed that exons 3 and 4 from MTS
(gray exons in ﬁg. 4b) are attached at the 3′ end of exon
38 of TAF1. Quantitative RT-PCR analysis by the TaqMan
assay with ﬁve probes designed to detect the previously
proposed MTS transcripts MTS-V4—which was regarded
as a candidate transcript for DYT3 because of a deduced
amino-acid change9—MTS-37/1, MTS-37/3, MTS-2/3, and
MTS-32′/34′ (ﬁg. 4b) yielded very weak and irregular am-
pliﬁcation signals that did not allow quantiﬁcation of ex-
pression levels in the caudate nucleus (table 6), whereas
the probe MTS-3/4 for exons 3 and 4 attached to TAF1
yielded a relatively weak but regular signal (table 6). These
results consistently suggested that the previously pro-
posed MTS transcripts may be extremely rare or unex-
pressed and that at least exons 3 and 4 of MTS may be
just an additional part of the 3′ UTR of TAF1, rather than
part of a new distinct short gene.
Decreased Expression of TAF1 in the XDP Brain
At least 10 new alternative splicing exons around TAF1
were found by long RT-PCR analysis (ﬁg. 4b), but neither
the DSCs nor the SVA insertion were located in any known
and predictably translated regions of the TAF1 exons. We
then examined the expression levels of various forms of
TAF1 in the XDP caudate nucleus, using quantitative RT-
PCR by designing speciﬁc probes for the TaqMan assay
(ﬁg. 5a). One of these probes, TA14-391—with an alter-
native exon of 6 additional bp, named “exon 34′”—
showed a highly signiﬁcant decrease in its expression level
in the caudate nucleus of the patient with XDP (ﬁg. 5a),
which was less than ∼1/40 of that in the normal control,
and its expression was virtually limited to brain and neu-
rons (table 7). TA14-391 was the second-most abundant
among all TAF1 species (ﬁg. 5a), and its expression level
in the control caudate nucleus was 1/4–1/5 of that of the
major form of TAF1 (table 7). TA14-391 also showed a
signiﬁcantly decreased level of expression in the cortex
and the nucleus accumbens of the patient with XDP (ﬁg.
5b), although these regions had no neuronal loss. These
ﬁndings suggest that the decreased level of expression was
the cause rather than the result of neuronal loss in the
caudate nucleus of the patient with XDP. In addition to
the TaqMan assay, in situ hybridization was performed in
the caudate by use of a riboprobe common to TAF1 iso-
forms that are located in exon 38 (probe 3 in ﬁg. 2a). The
riboprobe showed decreased expression in the caudate
neurons of the patient, although the weak expression was
still present in glial cells (ﬁg. 5e). Immunohistochemical
examination by use of a polyclonal antibody against the
common epitopes of TAF1 also showed decreased im-
munoreactivity in the XDP neurons in the caudate nu-
cleus from other patients with XDP (ﬁg. 5f). These ﬁndings
suggest that the deﬁciency of the neuron-speciﬁc isoform
of TAF1, TA14-391, reﬂects these histologically veriﬁed
neuron-speciﬁc decreases of TAF1 expression and that
TA14-391 is one of the neuron-speciﬁc isoforms, whereas
apparently similar levels of mRNA expression for TAF1 or
its isoforms as a whole (ﬁgs. 2b, 2c, and 5a) can be ac-
counted for by increased glial expression of TAF1 due to
intensive astrogliosis4,5 (ﬁg. 5d–5f), obscuring the de-
creased expression in neurons. The TA14-391 isoformmay
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Figure 6. a, Full-length cloning of a TAF1 isoform sequence containing alternative exon 34′. The 5′ end was obtained from CapSite
cDNA from brain. The 3′ end was obtained from Marathon-Ready cDNA from brain. The complete DNA sequences of these long products
were determined by a PCR direct-sequencing method by use of 28 redundant internal sequencing primers (red triangles). b, From the
long PCR products, products of sufﬁcient quantity and quality for PCR direct sequencing were ampliﬁed. NCp negative control without
DNA template. c, Each exon 34′–speciﬁc primer was designed to have only 3 nt of exon 34′, to prevent erroneous ampliﬁcation due to
slippage.
represent the decreased expression of many TAF1 isoforms
in the XDP neurons, because of its original neuron spec-
iﬁcity of expression. Finally, to determine the complete
structure of the isoform containing the 6 bp of exon 34′,
full-length cloning from libraries consisting of cDNAs en-
riched in their 5′ ends10 was performed. A single cDNA
containing exon 34′ was successfully cloned (ﬁg. 6), and
this had the complete translation frame of the major form
of TAF1 with an insertion of two amino acid residues,
alanine and lysine, in the carboxyl terminal kinase
domain.
Discussion
SVA retrotransposon insertions are thought to be active
in the human genome and to alter the expression level of
adjacent genes that cause diseases, such as autosomal re-
cessive hypercholesterolemia (ARH [MIM 605747])14 and
Fukuyama-type congenital muscular dystrophy (FCMD
[MIM 607440]).15 SVA insertion was found in the 3′ UTR
region of the FCMD gene and in an intronic region of the
ARH gene, which showed association with the reduced
expression level of these genes. SVA retrotransposon has
a high degree of GC content (∼70%) and a large number
of CpG sites (1150) in its nucleotide sequence, so that it
is frequently hypermethylated in its insertion site. In fact,
the present study demonstrated that the SVA retrotrans-
poson was hypermethylated in genomic DNA from the
caudate nucleus of the patient with XDP (ﬁg. 7), which
was also used in northern analysis, quantitative RT-PCR,
and in situ hybridization. Such hypermethylated status
and high GC content are able to affect dynamics of sur-
rounding nucleotide sequence, such as the cis-regulatory
element, so SVA insertionsmay reduce the expression level
of adjacent genes. For instance, many large introns of eu-
karyotes often contain tissue-speciﬁc cis-regulatory ele-
ments, such as enhancers or silencers.16–22 Intron 32, the
largest intron of TAF1 (29,932 bp), possibly contains a
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Figure 7. Detection of methylation around the SVA insertion. a,
Restriction sites around the SVA insertion. The HindIII fragment
and Southern probe are identical to those in ﬁgure 1a. The SVA
insertion created 47 new HpaII sites in the HindIII restriction
fragment. MspI is a CpG methylase-insensitive isoschizomer of
HpaII. b, Southern hybridization of genomic DNA from the patient’s
caudate. The 6.1-kb HindIII fragment was shifted, by additional
HpaII digestion, to an ∼4.6-kb fragment. By contrast, the HindIII
fragment was completely digested, by additional MspI digestion,
to a fragment of ∼2.4 kb.
neuron-speciﬁc cis-regulatory element. Although involve-
ment of other sequence variants in XDP pathogenesis is
still possible, it is most likely that the SVA insertion im-
pairs the function of a hypothetical neuron-speciﬁc cis-
regulatory element, such as an enhancer, through changes
in the methylation content and then substantially reduces
the expressions of many isoforms of TAF1, including
TA14-391, in the neurons. Because of the original neuron
speciﬁcity of the expression, the TA14-391 isoform might
represent the impairment more remarkably than do other
isoforms. On the other hand, the remaining expression,
as shown for TA14-391, despite being low, may compen-
sate for complete loss of function and may account for
the relatively late disease onset (age years) and39.5 8.44
the recessive mode of inheritance.
In summary, our results suggest that the SVA retrotrans-
poson insertion into the TAF1 gene may cause XDP by
altering the expression of TAF1 isoforms, including TA14-
391, possibly through DNA methylation changes. To our
knowledge, our report is the ﬁrst to reveal the entire ge-
nomic sequence of the DYT3 region and to demonstrate
at least one whole structure of the neuron-speciﬁc isoform
of TAF1 and the disease-speciﬁc mutation, with a possible
mechanism. To establish the disease speciﬁcity and the
involvement mechanism of the SVA insertion in reduced
expression of TAF1 in XDP, further studies, such as an
extensive population screening and genetic modiﬁcation
in model organisms, will be necessary and warranted. The
TAF1 protein is the largest and the essential component
of the TFIID complex in the pathway of RNA polymerase
II–mediated gene transcription,23,24 and it regulates tran-
scription of a large number of genes related to cell division
and proliferation.23–25 How can a ubiquitous gene such as
TAF1 cause a disease that affects a selective part of the
nervous system? We hypothesize that the neuron-speciﬁc
isoforms and/or their enhanced expression level of TAF1
(table 7) may play important roles in the nondividing cell.
Sharing similar pathological features in the caudate nu-
cleus, XDP and Huntington disease might result from dis-
orders in the same biochemical pathway of RNA poly-
merase II–mediated gene transcription. In Huntington
disease, for example, the abnormal huntingtin protein has
been shown to interfere with the interaction between Sp1
and TAFII130, resulting in reduced expression of DRD2
(MIM 126450) in the brain, including the caudate nu-
cleus.26 In XDP, the decreased expression of the TA14-391
isoform, and probably other TAF1 isoforms, may result in
transcriptional dysregulation of many neuronal genes, in-
cluding DRD2. We believe that the present ﬁndings in
XDP support the concept of “transcription syndromes”27
in TFIID, which include congenital cataracts facial dys-
morphism neuropathy (CCFDN [MIM 604168]) syn-
drome, caused by a partial deﬁciency of RNA polymerase
II28; Huntington disease26; dentato-rubro-pallidoluysian
atrophy (DRPLA [MIM 125370]),29 caused by interference
in the signals to TFIID; and spinocerebellar ataxia 17
(SCA17 [MIM 607136]),30 caused by an expanded poly-
glutamine in the TATA-binding protein (TBP [MIM
600075]).
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